

JT12 Rec'd PCT/PTO 0 3 SEP 2004

16

CLAIMS

1. Use of type 1 Placental Growth Factor (PLGF-1) for the preparation of a medicament promoting angiogenesis in the preventive or curative treatment of:

5       - diseases or pathological alterations involving the cutaneous or subcutaneous connective tissue, or

          - scleroderma, or

          - early skin ageing due to exposure to atmospheric aggressive agents or to protracted solar irradiation.

10       2. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 1, wherein the disease is localised scleroderma or progressive systemic scleroderma.

15       3. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 2, wherein the localised scleroderma is cutaneous and the progressive systemic scleroderma is myocardial scleroderma.

20       4. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 1, for the preparation of a medicament promoting angiogenesis in the preventive or curative treatment of the pathological loss of hair due to alopecia, hormonal disorders, chemotherapy, radiotherapy or medicament administration.

25       5. Use according to any one of claims 1 to 4, wherein the medicament is in a form suitable for generating a local or systemic effect.

30       6. Use according to any one of claims 1 to 5, wherein the medicament is in the form suitable for endovenous, intramuscular, intrarticular, subcutaneous administration, topical administration or by subcutaneous implant or ionophoresis.

      7. Use of type 1 Placental Growth Factor (PLGF-1) as promoter of cutaneous or subcutaneous angiogenesis in the prevention and cosmetic treatment of natural skin ageing.

35       8. Use of type 1 Placental Growth Factor (PLGF-1) as promoter of perifollicular angiogenesis in the prevention and in the cosmetic treatment of the natural loss of hair.

9. Use according to any one of claims 7 or 8, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

10. Use according to any one of claims 1 to 9, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 µg per Kg of body per day, preferably of 10 µg/Kg/day to 200 µg/Kg/day.

11. Pharmaceutical composition comprising PLGF-1 as active principle and a pharmaceutically acceptable excipient, characterised in that at least the 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least the 70% is in dimeric form and no more of the 1.5% is in monomeric form, and in that PLGF-1 is comprised in an amount from 50 µg to 30 mg per unitary dose for parenteral use and in an amount from 0.1 mg to 10 mg per gram of composition for topical use.

12. Cosmetic composition comprising PLGF-1 as active principle and a cosmetically acceptable excipient, characterised in that at least the 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least the 70% is in dimeric form and no more of the 1.5% is in monomeric form, and in that PLGF-1 is comprised in an amount from 0.01 mg to 0.09 mg per gram of composition.

13. Composition according to claims 11 or 12, characterised in that PLGF-1 is an expression product from genetically modified host cells (page 5, lines 23, 24) obtained in accordance with the method disclosed in the application PCT/IT02/00065 (WO-A-03/066676).

14. Pharmaceutical or cosmetic composition according to claim 11 to 13, characterised in that it is for local or systemic use and is in form of solution, lotion, W/O emulsion, O/W emulsion, suspension, liposome suspension, gel, cream, paste, ointment or subcutaneous implant.

15. Composition according to any one of claims 11 to 14, comprising one or more substances capable of stabilising the PLGF-1 in the active dimeric-multimeric forms.